Keywords
Terbutaline
Budesonide
Submitted : 2024-04-23
Accepted : 2024-05-08
Published : 2024-05-23
Abstract
Objective: To analyze the clinical effect of terbutaline combined with budesonide in the treatment of chronic obstructive pulmonary disease. Methods: 500 cases of patients with chronic obstructive pulmonary disease admitted to the hospital from January 2022 to December 2023 were selected and divided into 250 cases in the control group and 250 cases in the observation group by randomization method, both groups received conventional symptomatic treatment, with budesonide added to the control group and terbutaline and budesonide to the observation group, and the lung function indexes, therapeutic effects and adverse drug reactions before and after treatment were compared. Results: After treatment, the level of all lung function indexes of patients in the observation group was higher than that of the control group, and the level of total effective rate of treatment was 96.40%, which was higher than that of the control group (P < 0.05), and the difference in the incidence rate of adverse reactions between the two groups was not strong (P > 0.05). Conclusion: In the clinical treatment of chronic obstructive pulmonary disease, the combined use of terbutaline and budesonide can positively improve lung function, with precise effects and few adverse reactions.
References
Zhao X, 2023, Evaluation of Clinical Efficacy of Budesonide and Terbutaline Combined with Dihydroxypropyl Theophylline in the Treatment of Elderly Patients with Chronic Obstructive Pulmonary Disease. China Modern Drug Application, 17(9): 1–5.
Yi H, 2022, Effect of Terbutaline Combined with Budesonide Oxygen Atomized Inhalation on Lung Function Indexes in Patients with Chronic Obstructive Pulmonary Disease. Jiangxi Medicine, 57(12): 2089–2091.
Fu Y, Zhang N, 2022, Study on the Effect of Glucocorticoid Combined with Terbutaline on the Clinical Efficacy and Blood Gas Index of Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease. Guizhou Medicine, 46(12): 1874–1875.
Li J, Mi J, 2023, Clinical Study of Budesonide Formoterol Powder Inhaler Combined with Compound Ipratropium Bromide Solution Nebulization for Pulmonary Hypertension Complicated by Chronic Obstructive Pulmonary Disease. Guizhou Medicine, 47(2): 228–230.
Li C, Gao J, Wang H, et al., 2023, Efficacy of Budesonide Formoterol Powder Inhaler Combined with Montelukast in Treating Elderly Patients with Chronic Obstructive Pulmonary Asthma Overlap Syndrome. China Coal Industry Medical Journal, 26(1): 108–112.
Cai Y, Wu W, 2022, Analysis of the Effect of Budesonide Combined with Ipratropium Bromide Inhalation in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease. China Modern Drug Application, 16(12): 138–140.
Bian M, Bu L, 2022, A Controlled Study on the Effects of Budesonide Formoterol Inhaler and Budesonide Inhaler on Lung Function and Quality of Life in Patients with Chronic Obstructive Pulmonary Disease in Remission. Practical Drugs and Clinics, 25(1): 42–45.
Yan P, 2022, Effects of Budesonide Formoterol Powder Inhaler Combined with Montelukast Sodium on Patients with Asthma and Chronic Obstructive Pulmonary Overlap Syndrome. Journal of Medicine Forum, 43(13): 93–96.
Wang L, Xue T, Wang H, 2023, Clinical Effects of Montelukast Sodium Combined with Budesonide and Terbutaline in the Treatment of Patients with Asthma-Chronic Obstruction Pulmonary Overlap Syndrome. Clinical Medicine Research and Practice, 8(22): 77–80.
Wang D, 2023, Efficacy Analysis of Budesonide Powder Aerosol Combined with Terbutaline in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease. China Modern Drug Application, 17(5): 104–106.